Self-administering of an eye drop is simple and takes very little time (no waiting after administration). Patients should better adhere to their therapy and the therapeutic outcome may increase.
mu-Drop micro drops are packed in either a multi pack blister (e.g. a week medication for Glaucoma patients) or a frozen single pack blister (e.g. human serum for severe Dry Eye Syndrome patients).
In each product are 6 micro eye drops enough to administer medication in each eye. And even in the very unlikely event when the patient makes a mistake there are enough drops to correct.
The mu-Drop product is patented.
The mu-Drop eye drop technology platform is well documented in accordance with the relevant MDR, EP, ISO and MD guidelines.
mu-Drop also performed bioequivalence, pK and tolerability studies.
mu-Drop makes its documentation available to partners to facilitate and shorten the approval process for Marketing Approval.
For many years the medical community is aware that smaller eye drops are as efficient as larger eye drops and because less medication is administered and the micro drop fits in the eye, patients experience less side effects.
Pharma R&D has until recently not resulted in a cost effective micro eye drop which can be manufactured without major investments in equipment and regulatory support.
The mu-Drop applicator can be adapted for post sterilization for administering beta-blockers, aseptically filled with prostaglandins (both Glaucoma) and frozen stored when filled with human serum (severe Dry Eye Syndrome).
The mu-Drop applicator can prepared for single patients as well as manufactured in large volumes by allogeneically using donor serum. The manufacturing process is a fully closed system to increase product integrity and patient safety.
• Mu-Drop micro eye drops can be manufactured very efficiently
• Are significantly smaller than classic eye drops
• Require less API/serum
• Mu-Drop is licensing the technology to preferred partners.
